The most powerful MRI in the world studies the effects of COVID and myalgic encephalomyelitis / brain fatigue.

Published Date: 15 Mar 2023

For the first time in the world, researchers at Griffith University have used ultra-high magnetic field (7 Tesla) MRI to examine how COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS ) affect the same brain.

Read Full News

Latest News

Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Marco Meglio

Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

Understanding the Therapeutic Potential and Promising Early-Stage Data on Azetukalner for Focal Onset Seizures Marco Meglio

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

How Social Robotics and Embodied AI Could Reshape Neurology Care Neal K. Shah

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

Todays Updates

2024 Primary Stroke Prevention Guidelines: Key Takeaways and Clinical Implications Walter Kernan, MD, Isabella Ciccone, MPH

Walter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.

A Clinical Review of the 2025 Restless Leg Syndrome Guidelines Louie Pasculli, Andy Berkowski, MD, PhD

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis

Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

Todays Updates

2024 Primary Stroke Prevention Guidelines: Key Takeaways and Clinical Implications Walter Kernan, MD, Isabella Ciccone, MPH

Walter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.

A Clinical Review of the 2025 Restless Leg Syndrome Guidelines Louie Pasculli, Andy Berkowski, MD, PhD

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis

Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

Latest News

Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

Here's some of what is coming soon to NeurologyLive® this week.

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

News All Time

AES Poster Showcases Feasibility of Mobile App to Track Daily Self-Reporting Epilepsy Outcomes Isabella Ciccone, MPH

A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.

NeuroVoices: Richard Rammo, MD, on How Thalamic Neuromodulation is Evolving for Drug Resistant Epilepsy Marco Meglio, Richard Rammo, MD

The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.

FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia Isabella Ciccone, MPH

TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.

FDA Action Update, November 2025: Approvals, Clearance, and Boxed Warning Isabella Ciccone, MPH

Catch up on any of the neurology news headlines you may have missed in November 2025, compiled into 1 place by the NeurologyLive® team.

Long-Term Expanded Access Program Data Support Phase 3 Development of Bexicaserin in Developmental Epileptic Encephalopathies Marco Meglio

New findings reveal bexicaserin significantly reduces seizure frequency in patients with developmental and epileptic encephalopathies, supporting its advancement to phase 3 trials.

Survey identifies Fever-Related Seizure Reduction as Key Feature of CDKL5 Deficiency Disorder Louie Pasculli

A recent survey reveals fever significantly reduces seizure frequency in CDKL5 Deficiency Disorder, highlighting potential therapeutic strategies for patients.

PERC Analysis Highlights Factors Influencing Candidacy for Pediatric Drug-Resistant Epilepsy Surgery Isabella Ciccone, MPH

A new study presented at AES 2025 examined factors linked to declining surgery for pediatric drug-resistant epilepsy and highlighted variability in candidate selection across centers.

Inside the 2026 MDA Conference: Keynote Insights and Evolving Neuromuscular Care Marco Meglio, Sharon Hesterlee, PhD

Sharon Hesterlee, PhD, President and CEO of the Muscular Dystrophy Association, discussed the 2026 MDA Conference, the significance of its keynote speaker, and the evolving therapeutic landscape in neuromuscular medicine.

Stiripentol Reduces Seizure Burden in Patients with Lennox-Gastaut Syndrome, Study Shows Louie Pasculli

A new phase 2 study presented at AES 2025 showed that stiripentol may reduce seizure burden in patients with Lennox-Gastaut syndrome.

Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program Marco Meglio

The positive interim findings research represents the first clinical data for ETX101, an investigational cell-type-selective gene therapy, and the first potential one-time disease-modifying treatment for Dravet syndrome.

Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures Louie Pasculli

Findings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.

This Week on NeurologyLive® — December 8, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study Marco Meglio

Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.

Epidiolex CBD Treatment Effective Across Range of Developmental Epileptic Encephalopathies Marco Meglio

Recent analysis reveals Epidiolex significantly reduces seizures in patients with various developmental epileptic encephalopathies, showcasing its broad effectiveness.

NeurologyLive® Brain Games: December 7, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on autonomic dysfunction in long COVID!

AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome Marco Meglio

New AES 2025 data reinforce zorevunersen’s disease-modifying potential in Dravet syndrome, showing durable seizure reduction, functional improvements, and a consistent safety profile.

Recommended News For You

In early dementia, SSRIs enhance cognition and major depression.

Watch for Psoriasis After Cancer Immunotherapy, Study Says

Tipiracil hydrochloride and trifluridine tablets are approved by the USFDA for Natco Pharma.

Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.

tobacco use, the severity of their symptoms, and their desire to give up smoking among cancer survivors.

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

Obesity-related cancers are more likely in people who are obese in both healthy and unhealthy ways.

Recommended Articles For You

The Importance of Having a Quick and Effective Heparin Antidote  

Understanding SVR Normal Range: A Guide to Achieving Optimal Health 

The Statistical Evolution of Cancer Staging and Its Precision Impact on Prognosis and Therapy in Cancer Staging 2025 

Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Routine breast cancer screening can bring better outcomes for patients

2.

Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.

3.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

4.

Testosterone recovery linked to overall survival in high-risk prostate cancer

5.

Skinny melanoma incidence is associated with vitamin D deficiency.

1.

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation

2.

Targeting the Tumor Microenvironment: Next-Generation Strategies for Immuno-Oncology Success

3.

Apheresis vs. IVMP in Cancer Treatment: A Tale of Two Titans

4.

Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk

5.

Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

3.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

4.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

5.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot